I am a medical oncologist with interest in drug development and biomarker-driven therapies. This is a personal Profile | Views are Mine
Houston, TX
Joined September 2010
- Tweets616
- Following543
- Followers1.1K
- Likes2.5K
Pinned Tweet
Excited to share our article in @Annals_Oncology about Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)!
@MDAndersonNews @isliquidbiopsy
annalsofoncology.org/article…
Mohamed A Gouda retweeted
⭐️👉🏼Amazing to work on this review in @CellPressNews @CellCellPress @MedCellPress
👉🏼It started with a clinical question. One of my patients' glioblastoma transformed into gliosarcoma after treatment with BRAF & MEK inhibitor. Another patient's NSCLC adenocarcinoma became small cell lung cancer after RET inhibitor. A third patient's papillary thyroid cancer turned into anaplastic thyroid cancer again after BRAF inhibitor. @mgoudaMD & I started something from a clinical point of view. But we wanted more answers.
👉🏼Over coffee at an @AACR meeting, I asked the guru of EMT biology @SenduraiMani to look at this from the basic science/ translational point of view. From that conversation, a comprehensive search and this review were born. Wonderful to work with his team on this one. It took around 2 years to get this done but learned a lot on this.
⭐️⭐️⭐️If we want the next generation of cancer therapies to last, we have to treat cancer as an evolving system, not a static target.
cell.com/med/abstract/S2666-…
🚨 Hot off the press! A week before @myESMO annual meeting for everyone to read 👉
🔥Pleased to share with the 🌎our comprehensive review in @CellPressNews @MedCellPress journal Med:
👉“Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology”
👉Precision oncology has transformed cancer therapy, but tumors adapt.
👉One of the most striking escape routes is histological transformation: a cancer that responds beautifully to targeted therapy can change its very identity, from adenocarcinoma to small cell or squamous for example.
👉In this review we examine:
🔹 How different forms of tumor plasticity drive histological transformation as a resistance mechanism across anticancer therapies
🔹 The underlying biology + mechanisms behind these lineage switches
🔹 How precision oncology, informed by a deeper understanding of plasticity, can be used to anticipate, detect + overcome transformation + improve outcomes for patients
👉If we want the next generation of cancer therapies to last, we have to treat cancer as an evolving system, not a static target.
Grateful to an army of amazing co-authors, led by Nick A. Kuburich & @mgoudaMD , with Breanna R. Demestichas, Preetesh Jain, Petra den Hollander, Evgeny Yakirevich, @WIN_Consortium leadership @Dr_R_Kurzrock , @weldeiry , and the one & only guru of EMT @SenduraiMani
#PrecisionOncology #CancerResearch #DrugResistance #TumorPlasticity #EMT #OncTwitter
🧵 A thread soon with the behind-the-scenes story of how this paper came together. Stay tuned! @OncoAlert @oncodaily
🔗 cell.com/med/abstract/S2666-…
Mohamed A Gouda retweeted
🚨 Hot off the press! A week before @myESMO annual meeting for everyone to read 👉
🔥Pleased to share with the 🌎our comprehensive review in @CellPressNews @MedCellPress journal Med:
👉“Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology”
👉Precision oncology has transformed cancer therapy, but tumors adapt.
👉One of the most striking escape routes is histological transformation: a cancer that responds beautifully to targeted therapy can change its very identity, from adenocarcinoma to small cell or squamous for example.
👉In this review we examine:
🔹 How different forms of tumor plasticity drive histological transformation as a resistance mechanism across anticancer therapies
🔹 The underlying biology + mechanisms behind these lineage switches
🔹 How precision oncology, informed by a deeper understanding of plasticity, can be used to anticipate, detect + overcome transformation + improve outcomes for patients
👉If we want the next generation of cancer therapies to last, we have to treat cancer as an evolving system, not a static target.
Grateful to an army of amazing co-authors, led by Nick A. Kuburich & @mgoudaMD , with Breanna R. Demestichas, Preetesh Jain, Petra den Hollander, Evgeny Yakirevich, @WIN_Consortium leadership @Dr_R_Kurzrock , @weldeiry , and the one & only guru of EMT @SenduraiMani
#PrecisionOncology #CancerResearch #DrugResistance #TumorPlasticity #EMT #OncTwitter
🧵 A thread soon with the behind-the-scenes story of how this paper came together. Stay tuned! @OncoAlert @oncodaily
🔗 cell.com/med/abstract/S2666-…
Mohamed A Gouda retweeted
🆕👇🏽Unveiling FULL results of our #NEST🪺 Trial in MSS “cold”🧊colorectal cancer
💡Immunotherapy (BOT🤖/BAL) BEFORE surgery
💯% disease-free to date✅
NEST1:~32 months
NEST2:~24 months
5 years of work—now in @CCR_AACR🙌🏽
🚀#NEST3 NOW OPEN!
@OncoAlert
🔗 aacrjournals.org/clincancerr… – at Irvine, CA
Mohamed A Gouda retweeted
It was a true pleasure to chat with @biannagolodryga & @0xfoo on @cnni the potential impact of the recent results from the @moderna_tx & @Merck P3 trial with mRNA-based vaccine in patients with high risk melanoma. Much can be built on this platform to improve the outcomes of patients with cancer. edition.cnn.com/2026/08/25/t…
Mohamed A Gouda retweeted
This is a landmark moment in melanoma, cancer immunology, & IO drug development at large. Checkpoint inhibitors have allowed us to uncover & amplify the immune impact of cancer therapies we used for decades (e.g.,chemo, RT). Now, coupled with the powerful mRNA vaccine technology, finally unlocked the potential for personalized immunotherapy. Congrats to @Merck & @moderna_tx Grateful for our patients & research teams that allowed to participate in such a monumental accomplishment!
A promising step forward in melanoma treatment. 🧬💙
Merck and Moderna announced positive Phase 3 results from the INTerpath-001 trial, showing that an investigational, personalized mRNA-based therapy, intismeran autogene (V940), combined with KEYTRUDA, significantly improved recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone in people with completely resected stage IIB-IV melanoma.
This is the first positive Phase 3 readout for an individualized neoantigen therapy and marks an important milestone for personalized cancer treatment. The therapy is designed using the unique genetic “fingerprint” of each patient’s tumor to help train the immune system to recognize and fight cancer cells.
The study will continue to evaluate overall survival, and the full data will be presented at an upcoming medical meeting and shared with regulators.
For people facing melanoma, every advance matters. Every breakthrough brings us closer to a future where more people can live longer—and live melanoma-free. 💙
merck.com/news/merck-and-mod…
#Melanoma #MelanomaResearch #CancerResearch #Immunotherapy #mRNA #ClinicalTrials
Mohamed A Gouda retweeted
🧬 Liquid biopsy may be transforming precision oncology—but are healthcare systems keeping up?
Article 📰
sciencedirect.com/science/ar…
Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB) done in collaboration with OncoAlert 🚨
A global survey of 393 oncology providers across 59 countries 🌐 reveals that liquid biopsy 🩸 is widely valued but inconsistently implemented.
➡️ While 88% consider it important, use remains limited, with major differences by region, income level, and practice setting. Cost, test availability, interpretation challenges, and turnaround time were key barriers.
✅ Structured workflows and molecular tumor board support also varied substantially, highlighting the need for context-specific strategies to expand equitable implementation.
@eleonora_nicolo
@SurbhiSinghalMD
@ESaldanhaMD
@KonVenetis
@letipontolillo
@ddemiguelperez
@AngeloDipa_
@nnadiagee
@PasqualePisapia
@A_OrtegaFranco
@mgoudaMD
@DrMirallas
@ErulEnes
@weoncologists
@RobertoBoreaMD
@ReduzziCarol
@isliquidbiopsy
Pinging
@ChristianRolfo
@UmbertoMalapel1
@matteolambe
@DrYukselUrun
@tompowles1
@PGrivasMDPhD
@scocmem
@nataliagandur
@to_be_elizabeth
@CathyEngMD
@BenWestphalen
@graokane
@christine_lovly
@BRicciutiMD
@UOzkerim
@DrVilmaPBarcia
@DraMartinezLago
Mohamed A Gouda retweeted
⭐️Such a delight to be at the -“STOP cancer meeting” - Summit for Novel therapies in Oncology & Precision Medicines in Cancer. Fantastic colleagues presenting today @MiteshBorad @mgoudaMD @AliSchram @EileenMOReilly @OncoAlert @oncodaily !
RP1 is now FDA approved!
Today, FDA granted approval to a genetically modified oncolytic viral therapy for adults with resistant advanced melanoma. This approval underscores FDA’s commitment to using every available regulatory tool to help bring meaningful treatment options to patients with serious diseases. fda.gov/news-events/press-an…
ALT Image with a green background displaying the FDA logo. Text reads, "Biologic Approval. FDA approves engineered viral immunotherapy for patients with treatment‑resistant advanced Melanoma." There are illustrations of medical items like bottles and a syringe.
Mohamed A Gouda retweeted
Wow!
In January 1995 I was told I had three years to live. I never found a marrow donor. In August 1998 I entered a Phase 1 clinical trial at MD Anderson for what became Gleevec. Thirty-one years later I’m still here. Clinical trials don’t just advance science — they give patients a second chance at life.
Read more about why equitable access to trials matters: ascopubs.org/doi/10.1200/EDB…
#Gleevec #Imatinib #TKI #ClinicalResearch #ClinicalTrial #CML #ChronicMyeloidLeukemia #KinaseInhibitor
Mohamed A Gouda retweeted
UT MD Anderson is proud to be named No.1 in the nation for cancer care in @USNews’ “Best Hospitals” ranking.
Read more: spr.ly/6010BE7x5O #BestHospitals #EndCancer
ALT UT MD Anderson is #1 in the nation for cancer care, with white text. Below are the UT MD Anderson Cancer logo and a gold USNews Best Hospitals Cancer 2026-2027 badge, on a red-purple gradient background.
Mohamed A Gouda retweeted
New #JITC article: "Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors" jitc.bmj.com/content/14/6/e0…
@MDerbalaMD @ANaingMD @BettzyStephen @HajjarJoud @mgoudaMD @Abdul_Zarifa
Mohamed A Gouda retweeted
Thank you for highlighting my candidacy @sitcancer
Today is last day to vote!
Discover more about 2026 SITC At-Large Director candidate, Hussein Tawbi, MD, PhD
(The University of Texas MD Anderson Cancer Center). Read Dr. Tawbi’s bio and position statement: sitcancer.org/get-involved/2…
Mohamed A Gouda retweeted
Headed to #AACR26, the same week we had practice changing clinical trial data in #PancreaticCancer with a KRAS inhibitor.
Reminded of this critique that @Pasca_Lab received on her grant in 2013 - "There are not, and will never be, KRAS inhibitors".
Keep calm & science on!
Mohamed A Gouda retweeted
⭐️🚨 🧬 Hot off the press 👉🏼A new chapter in cancer biology’s foundational text 👉🏼
🚨Hanahan’s “Hallmarks of Cancer-Then and Now, and Beyond” drops in @CellCellPress updating the framework that has shaped 25 years of oncology research, precision oncology & clinical trials
The roadmap evolves. Required reading @OncoAlert 📌
cell.com/cell/fulltext/S0092…
Mohamed A Gouda retweeted
💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update
If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0:
📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades.
🧪 Neutrophils:
Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded.
Stricter G4: threshold drops from <500 to <100/mm³.
🩸 Platelets (Thrombocytopenia):
Wider G3: Now covers 10k–50k (previously 25k–50k).
Stricter G4: threshold drops from <25k to <10k/mm³.
v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria.
Overall, IMO these new thresholds align better with clinical practice.
#ClinicalTrials #MedEd #OncTwitter #DrugSafety
Important to recognize the top reason is not that the drug didn't work! @DavidHongMD used to tell us in clinic about molecules that were potentially effective but sadly discontinued. Enforcing publication of data from terminated trials is important for future generations!
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023 nature.com/articles/d41573-0…
Important article! Sadly, equally important (and less discussed) is overlooking poorly conducted systematic reviews and meta-analyses. Despite being atop the evidence pyramid, some are pursued by students/trainees as an easy way of publishing - often without the rigor required!
Check our viewpoint published @JAMA_current #MedEd
Abstract Factory—Research Culture Harming Medical Education
The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.
➡️jamanetwork.com/journals/jam…
@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG
Mohamed A Gouda retweeted
In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared. Learn more: nej.md/4907cG5
ALT A figure showing the presence or absence of organ damage after immune checkpoint inhibitor therapy.